Otwarty dostęp

MRI features and prognostic evaluation in patients with subventricular zone-contacting IDH-wild-type glioblastoma

, , ,  oraz   
30 maj 2025

Zacytuj
Pobierz okładkę

Figure 1.

The anatomical relationship between glioblastoma and the subventricular zone (SVZ). (A) Contrast-enhancing tumor lesions that do not contact the SVZ are classified as the SVZ non-contact group. (B) Contrastenhancing tumor lesions that contact the SVZ are classified as the SVZ contact group.
The anatomical relationship between glioblastoma and the subventricular zone (SVZ). (A) Contrast-enhancing tumor lesions that do not contact the SVZ are classified as the SVZ non-contact group. (B) Contrastenhancing tumor lesions that contact the SVZ are classified as the SVZ contact group.

FIGURE 2.

Glioblastomas with SVZ contact are further divided into four groups according to the specific regions of the lateral ventricle contacted. (A) Tumor contacting the frontal horn of the left lateral ventricle. (B) Tumor contacting the body of the left lateral ventricle. (C) Tumor contacting the temporal horn of the right lateral ventricle. (D) Tumor contacting the occipital horn of the right lateral ventricle.
Glioblastomas with SVZ contact are further divided into four groups according to the specific regions of the lateral ventricle contacted. (A) Tumor contacting the frontal horn of the left lateral ventricle. (B) Tumor contacting the body of the left lateral ventricle. (C) Tumor contacting the temporal horn of the right lateral ventricle. (D) Tumor contacting the occipital horn of the right lateral ventricle.

Figure 3.

Axial (A) and coronal (B) contrast-enhanced T1-weighted MR images of a GBM patient with multifocal manifestations. Panels (C) and (D) illustrate another GBM patient with a tumor crossing the midline, where the contrast-enhanced lesion extends from the corpus callosum to the contralateral hemisphere.
Axial (A) and coronal (B) contrast-enhanced T1-weighted MR images of a GBM patient with multifocal manifestations. Panels (C) and (D) illustrate another GBM patient with a tumor crossing the midline, where the contrast-enhanced lesion extends from the corpus callosum to the contralateral hemisphere.

FIGURE 4.

Kaplan-Meier curves for overall survival in glioblastoma: (A) Patients with and without SVZ contact; (B) Patients with tumors contacting specific SVZ regions.
SVZ =subventricular zone
Kaplan-Meier curves for overall survival in glioblastoma: (A) Patients with and without SVZ contact; (B) Patients with tumors contacting specific SVZ regions. SVZ =subventricular zone

Univariate and multivariate Cox regression analyses for overall survival in glioblastoma patients

Parameter Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.025 1.015–1.036 < 0.001* 1.024 1.014–1.034 < 0.001*
Gender 1.009 0.817–1.247 0.933
Tumor size 1.112 1.039–1.190 0.002* 1.053 0.966–1.148 0.239
Peritumoral edema 0.950 0.876–1.029 0.207
Tumor shape 0.783 0.513–1.195 0.257
Enhancement type 0.687 0.475–0.993 0.046* 0.771 0.532–1.117 0.170
Enhancement degree 1.004 0.732–1.377 0.980
Cystic lesion 0.904 0.722–1.133 0.383
Necrosis 1.008 0.519–1.956 0.982
Multifocal lesions 1.635 1.201–2.225 0.002* 1.548 1.111–2.158 0.010*
Crossing the midline 1.763 1.196–2.599 0.004* 1.415 0.936–2.138 0.099
SVZ contact 1.650 1.326–2.052 < 0.001* 1.364 1.037–1.794 0.027*

Comparison of clinical and MRI characteristics between the subventricular zone contact and non-contact groups

Characteristic SVZ Contact (n = 239) SVZ Non-contact (n = 132) p value
Age (year) 65 ± 11 63 ± 10 0.085
Gender, n (%) 0.237
 Male 149 (62.3) 74 (56.1)
 Female 90 (37.7) 58 (43.9)
OS (month) 11.0 (5.0–18.0) 17.5 (12.0–28.5) < 0.001*
Tumor size (cm) 5.07 ± 1.35 3.31 ± 1.12 < 0.001*
Peritumoral edema (cm) 1.83 (1.02–2.70) 1.70 (0.55–2.62) 0.192
Tumor shape/n (%) 0.016*
 Regularity 10 (4.2) 14 (10.6)
 Irregularity 229 (95.8) 118 (89.4)
Enhancement type/n (%) 0.030*
 Ring 15 (6.2) 17 (12.9)
 Non-ring 224 (93.8) 115 (87.1)
Enhancement degree/n (%) 0.386
 Significant 212 (88.7) 113 (85.6)
 Non-significant 27 (11.3) 19 (14.4)
Cystic lesion/n (%) 0.004*
 Yes 83 (34.7) 27 (20.5)
 No 156 (65.3) 105 (79.5)
Necrosis/n (%) 0.011*
 Yes 237 (99.2) 125 (94.7)
 No 2 (0.8) 7 (5.3)
Multifocal lesions (%) 0.050
 Yes 37 (15.5) 11 (8.3)
 No 202 (84.5) 121 (91.7)
Crossing the midline (%) < 0.001*
 Yes 28 (11.7) 0 (0.0)
 No 211 (88.3) 132 (100.0)
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Medycyna, Medycyna kliniczna, Medycyna wewnętrzna, Hematologia, onkologia, Radiologia